FibroBiologics, Inc. (FBLG) Price & Analysis

Compare

229 Followers

FBLG Stock Chart & Stats

$0.38

-$0.09(-3.98%)

At close: Jan 08 4:00 PM EST

$0.38

-$0.09(-3.98%)

Day’s Range― - ―

52-Week Range$0.22 - $2.13

Previous CloseN/A

Volume56.64K

Average Volume (3M)978.93K

Market Cap

$22.48M

Enterprise Value$25.97M

Total Cash (Recent Filing)$4.87M

Total Debt (Recent Filing)$7.11M

Price to Earnings (P/E)―

Beta0.51

Next Earnings

Apr 06, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding66,519,720

10 Day Avg. Volume1,423,641

30 Day Avg. Volume978,931

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)24.04

Price to Sales (P/S)0.00

P/FCF Ratio-5.44

Enterprise Value/Market Cap1.16

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-112.42

Enterprise Value/Ebitda-1.46

Forecast

1Y Price Target

$3.25

Price Target Upside755.26% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentPhase 1/2 development for CYPS317 would build on encouraging preclinical results including single dosing matching or exceeding therapeutic effects of multiple doses of anti-IL-23 monoclonal antibodies based on animal models.

Regulatory DevelopmentsThe company announced filing its Phase 1/2 IND application with the FDA for allogeneic fibroblast spheroid-based therapy CYPS317, for the treatment of moderate-to-severe psoriasis.

Bears Say

Stock PerformanceThe stock has been down over -80% YTD, while the NBI is up over +20% YTD.

FibroBiologics, Inc. News

FibroBiologics CEO says 2026 ‘will be about execution’

FibroBiologics (FBLG) issued a letter to shareholders, which read in part, “Looking back on 2025, I’m reminded of...

6d ago

FBLG

FibroBiologics announces preclinical results for FSdC

FibroBiologics (FBLG) announced preclinical results for FSdC, an investigational FSdC spheroid-based therapy, demonstrating superior improvement in recovering intervertebral...

8d ago

FBLG

FibroBiologics files IND application to initiate clinical trials of CYPS317

FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and...

13d ago

FBLG

FibroBiologics files to sell 22.5M shares of common stock for holders

16:04 EST FibroBiologics (FBLG) files to sell 22.5M shares of common stock for holders Published first on TheFly...

21d ago

FBLG

Vanguard Total Stock Market ETF (VTI) Daily Snapshot—12/23/25

The Vanguard Total Stock Market ETF ($VTI), which provides broad exposure to the entire U.S. stock market, is...

21d ago

VTI

Vanguard Total Stock Market ETF (VTI) Daily Update—12/22/25

The Vanguard Total Stock Market ETF ($VTI), which provides broad exposure to the entire U.S. stock market, is...

22d ago

VTI

AAPL

Vanguard Total Stock Market ETF (VTI) Daily Update—12/17/25

The Vanguard Total Stock Market ETF ($VTI), which provides broad exposure to the entire U.S. stock market, is...

27d ago

HPP

Vanguard Total Stock Market ETF (VTI) Daily Update—12/16/25

The Vanguard Total Stock Market ETF ($VTI), which offers broad exposure to the entire U.S. stock market, was...

28d ago

HPP

FibroBiologics prices 5.23M shares at 33c in registered direct offering

FibroBiologics (FBLG) entered into definitive agreements for the issuance and sale of an aggregate of 5,227,275 shares of...

29d ago

FBLG

FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split

An update from FibroBiologics, Inc. ( ($FBLG) ) is now available. On July 1, 2025, FibroBiologics, Inc. was...

11d ago

FBLG

FibroBiologics Enters Securities Purchase Agreement

FibroBiologics, Inc. ( ($FBLG) ) just unveiled an announcement. On December 14, 2025, FibroBiologics, Inc. entered into a...

29d ago

FBLG

Vanguard Total Stock Market ETF (VTI) Daily Update—12/12/25

The Vanguard Total Stock Market ETF ($VTI) provides investors with broad access to the entire U.S. stock market....

1M ago

HPP

LXP

VTI ETF Daily Update—12/11/25

The Vanguard Total Stock Market ETF ($VTI) provides investors with broad access to the entire U.S. stock market....

1M ago

HPP

LXP

FibroBiologics submits new patent application with USPTO

FibroBiologics (FBLG) announced that it has submitted a new patent application with the U.S. Patent and Trademark Office,...

1M ago

FBLG

FBLG FAQ

What was FibroBiologics, Inc.’s price range in the past 12 months?

FibroBiologics, Inc. lowest stock price was $0.22 and its highest was $2.13 in the past 12 months.

What is FibroBiologics, Inc.’s market cap?

FibroBiologics, Inc.’s market cap is $22.48M.

When is FibroBiologics, Inc.’s upcoming earnings report date?

FibroBiologics, Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 83 days.

How were FibroBiologics, Inc.’s earnings last quarter?

FibroBiologics, Inc. released its earnings results on Oct 31, 2025. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.01.

Is FibroBiologics, Inc. overvalued?

According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does FibroBiologics, Inc. pay dividends?

FibroBiologics, Inc. does not currently pay dividends.

What is FibroBiologics, Inc.’s EPS estimate?

FibroBiologics, Inc.’s EPS estimate is -0.09.

How many shares outstanding does FibroBiologics, Inc. have?

FibroBiologics, Inc. has 66,519,720 shares outstanding.

What happened to FibroBiologics, Inc.’s price movement after its last earnings report?

FibroBiologics, Inc. reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went up 0.254%.

Which hedge fund is a major shareholder of FibroBiologics, Inc.?

Currently, no hedge funds are holding shares in FBLG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FibroBiologics, Inc.

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

FibroBiologics, Inc. (FBLG) Earnings & Revenues

Historic Earnings Reports

FBLG Stock 12 Month Forecast

Average Price Target

$3.25

▲(755.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.224,0.5913846153846154,0.9587692307692307,1.326153846153846,1.6935384615384614,2.060923076923077,2.4283076923076923,2.795692307692308,3.163076923076923,3.5304615384615383,3.897846153846154,4.26523076923077,4.632615384615384,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.224,0.45676923076923076,0.6895384615384615,0.9223076923076923,1.1550769230769231,1.3878461538461537,1.6206153846153846,1.8533846153846152,2.086153846153846,2.318923076923077,2.5516923076923077,2.7844615384615383,3.0172307692307694,{"y":3.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.224,0.3221538461538462,0.4203076923076923,0.5184615384615385,0.6166153846153847,0.7147692307692308,0.812923076923077,0.9110769230769231,1.0092307692307694,1.1073846153846154,1.2055384615384617,1.3036923076923077,1.401846153846154,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.763,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.648,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.621,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.523,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.393,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.261,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.224,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >